Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy

Leuk Lymphoma. 2021 Feb;62(2):498-500. doi: 10.1080/10428194.2020.1832674. Epub 2020 Oct 10.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azacitidine / adverse effects
  • DNA Methylation
  • Glycine / analogs & derivatives
  • Humans
  • Hydroxamic Acids*
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics
  • Treatment Outcome

Substances

  • Hydroxamic Acids
  • tosedostat
  • Azacitidine
  • Glycine

Associated data

  • ClinicalTrials.gov/NCT02452346